Financial Summary (All financials)
| In millions, except per share items | Dec-31-22 | Dec-05-22 | Dec-31-21 | Dec-05-21 | Dec-31-20 | Dec-31-19 |
| Revenues | 0.0 | 43.0 | 0.0 | 20.6 | 0.0 | 1.8 |
| Revenue growth | | 108.4% | | | -100.0% | |
| Cost of goods sold | 0.0 | 58.9 | 0.0 | 26.3 | 0.0 | 3.1 |
| Gross profit | 0.0 | -15.9 | 0.0 | -5.7 | 0.0 | -1.3 |
| Gross margin | | -37.0% | | -27.4% | | -74.4% |
| Research and development | 43.0 | | 20.6 | | 7.2 | |
| General and administrative | 15.9 | 15.9 | 5.7 | 5.7 | 2.1 | 1.3 |
| EBIT | -58.9 | -58.9 | -26.3 | -26.3 | -9.3 | -3.1 |
| EBIT margin | | -137.0% | | -127.4% | | -174.4% |
| Pre-tax income | -55.3 | 0.0 | -26.3 | 0.0 | -9.3 | 0.0 |
| Income taxes | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Net income | -55.3 | 0.0 | -26.3 | 0.0 | -9.3 | 0.0 |
| Net margin | | 0.0% | | 0.0% | | 0.0% |
| |
| Diluted EPS | ($1.32) | $0.00 | ($1.91) | $0.00 | ($6.05) | $0.00 |
| Shares outstanding (diluted) | 41.9 | 41,883.9 | 13.8 | 13,780.5 | 1.5 | 2,650.4 |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|